Skip to main content
High Contrast
|
Reset
-A
A
+A
Notices
|
Media Release
|
Trading Holidays
|
BSEPlus
|
BSE SME
|
Payments to BSE
|
Contact us
|
Careers
|
FeedBack
|
(Indicative Close)
Get Quote
quote options
Equity T+1
Equity T+0
Derivatives
MF/ETFs
Debt/Others
Currency Derivatives
Commodity Derivatives
Electronic Gold Receipts
Hybrid Security
Municipal Bonds
SSE
Menu
Home
About BSE
Investors Relations
Markets
Public Issues/OFS/SGB
Corporates
Members
Investment Advisers
Research Analysts
Investors
Market Data Products
Corporates
Get Listed
Get Listed
Listing Instruments
Equity Shares
Debt
IDR
Non-Convertible Redeemable Pref. Shares
Perpetual Non-Cumulative Preference Shares
Listing on SME platform
Innovators Growth Platform (IGP)
BSE Hi-Tech
Mutual Funds / ETF
Alternate Investment Fund
InviTs
REITs
Commercial Paper (CP)
Benefits of Listing
Listing Fees
Listing Regulations & Agreement
Master Checklist for Listing
Direct Listing (without IPO)
BSEPSU.com
Checklist for Accredited Investors
Corporate Filings
Corporate Filings
Corporate Announcements
Corporate Actions
Financial Results
Board Meetings
Cancelled / Revised
Shareholders Meetings
Voting Results
Result Calendar
Shareholding Patterns
Corporate Governance Scorecard
Corporate Governance
Offer Documents
Schemes under Regulation 37
Sustainability Reports
Historical Annual Reports
XBRL Filings
XBRL to Excel converter
XBRL
Disclosures Submitted by Company
Insider Trading 1992
Insider Trading 2015
SAST
Pledge
Reasons for Encumbrance
SAST Annual Disclosures
Consolidated - Pledge data
PIT Trading Plan
System Based Disclosures
Insider Trading 2015
SAST
Pledge
SAST Annual Disclosures
Continual Disclosure under Insider Trading Regulation (w.e.f. October 01, 2020)
Information Memorandum
QIP Equity
Institutional Placement – InvITs
Institutional Placement – REIT
Scheme of Arrangement
Companies listed under Direct Listing
Revocation
PIT Mutual Funds
Off market transaction – Reg 5D(1) (i)
Trading Plan – Reg 5D(1)(iv)
Quarterly Disclosures - Reg 5E (1) – RTA
Event based disclosures – Reg 5E (2) – RTA
UPSI declaration
Compliances and Other Info
Compliance
Listing Centre
Circulars to Listed Companies
SEBI Clarifications on Insider Trading
Downloads
Compliance Calender
Revocation of Securities
SOP Non Compliance under LODR
Companies Eligible for Offer for Sale
Rating Action by CRA’s
FAQs on Listing
FAQs on Business Responsibility Report
Compulsory Delisting
Companies Suspended for more than 7 years
Companies under IBC
Non Payment of Listing Fee Dues
CRA - Sharp Rating Actions
Non-Compliance of DN Database
Master circular for Listing Compliance
ESG Rating
Corporate and Other Info
Delisted companies
Companies with name change
Buy back
Industry classification
Listed Securities
Corporate Governance Scorecard
Independent Directors Databank portal
Corporate Group Repository
Historical Data
Compliance Status for Companies
Historical Compliance
SEBI order on MPS
SEBI relaxation for MPS
Company Mergers
Corporate Announcement
Security Code :
531633
Company :
LINCOLN
Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain
Exchange Disseminated Time
Lincoln Pharmaceuticals Ltd has informed BSE regarding a Press Release dated February 07, 2011 titled "Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain"
Press Release :
"Lincoln Pharmaceuticals Limited (LPL), Ahmedabad based world class pharmaceutical company recognized for manufacturing top class quality Health Care Products, announced the launch of a novel drug delivery system in Paracetamol, Pa-12 - India's first Long-Acting Paracetamol (Long-acting pain medications stay in your system for an extended period of time) for long term relief from fever and pain at a press conference in the city today. Paracetamol is the time tested molecule that controls fever and pain by working on the hypothalamus gland of the human brain. In comparison to conventional oral paracetamol tablets, Indian' clinical trials have proven Pa12 to be more effective with longer acting action and fewer side effects. Pa-12 contains 1000mg paracetamol, programmed for "Hon-Stop 12 hours fever control with 1 tab only". In a day a patient will need only two tablets of Pa-12 instead of 3 to 4 tablets of conventional oral paracetamol tablets.
Under the conventional treatment for fever and pain, patients are given 500 mg or 650 mg tablets of paracetamol which may exhibit some limitation related to repeat dosages in 24 hours. Moreover the side effect profile is higher with higher frequency of dosage regimens. To find a solution to this problem, LPL carried out two years of indigenous research and developed a novel drug delivery system with a new, formulation for a Long Acting Paracetamol, Pa-12. Clinical trials of more than 500 patients at leading Indian hospitals have proven and established the efficacy and tolerability of this product in comparison to other paracetamol brands available in the market.
Speaking at the press conference on the launch of the new drug delivery system, PA-12 Mr. Mahendra G Patel, MD, Lincoln Pharmaceutical Ltd. said "We are very excited by this latest innovation from our R&D facility. Our endeavor to constantly develop new formulations with the goal of providing improved healthcare products, for better treatment has again paid off. The launch of Pa-12 with its advanced formulation will provide relief to people suffering from pain and high temperature more effectively. With just a single tablet the patient's pain and fever will be acted upon for 12 hours at a stretch with lower, side effects. The initial test phase in the market has been very encouraging and we are sure that the formulation will be well accepted by the medical foraternity".
Speaking on this occasion Mr. Rajani G Patel, Joint Managing Director, Lincoln Pharmaceutical Ltd. said, "Pain and fever is a problem associated with several illnesses. With our company motto being "Healthcare for All" it was only natural for us to try and find a better remedy for the suffering patients Now with the Pa-12 providing longer lasting treatment with a single dosage it is certainly going to be a boon for many. We at Lincoln Pharmaceutical Ltd are very happy to be a part of the solution" He further added, "We have applied for a patent for this novel drug delivery system of Paracetamol. While we are initially launching Pa-12 in the domestic market, we have plans to market this product internationally as well. This new launch will strengthen our position in the pharmaceutical industry and will pave the path for stupendous growth."
Disclaimer
Back To Announcements